Common use of Ownership of Sponsor Drug Clause in Contracts

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution Provider and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.. 5.6

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution Provider and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.. 5.5

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator Healthcare Provider no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Institutionand Principal Investigator no Investigatorno express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of SponsorSponsor or its designee. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug4.4.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. Vlastnictví Hodnoceného Léčivého Přípravku. Hodnocený léčivý přípravek je a zůstává vlastnictvím zadavatele. Zadavatel neuděluje zdravotnickému zařízení ani hlavnímu zkoušejícímu žádná výslovná ani předpokládaná práva duševního vlastnictví k hodnocenému léčivému přípravku nebo k jakýmkoliv metodám výroby nebo používání hodnoceného léčivého přípravku.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. 5.4 Vlastnictví hodnoceného léčivého přípravku. Hodnocený léčivý přípravek je a zůstává majetkem zadavatele. Zadavatel neuděluje instituci žádná výslovná ani předpokládaná práva duševního vlastnictví k hodnocenému léčivému přípravku ani k jakékoliv metodě přípravy a použití hodnoceného léčivého přípravku.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. with the exception of what is needed to implement the Protocol.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator Provider no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. dobu jeho provádění bylo klinického hodnocení pod trvalým dohledem NEK.

Ownership of Sponsor Drug. Sponsor Drug is and remains Comparator Drug are and will remain the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.. 4.5

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. klinického hodnocení, vrátí Zdravotnické zařízení a Hlavní zkoušející zadavateli. Toto ujednání se vztahuje i na veškerá léčiva dodaná Zadavatelem v rámci klinického hodnocení, u nichž uběhla doba použitelnosti.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug. 5.4 Vlastnictví hodnoceného léčivého p řípravku. Hodnocený léčivý přípravek je a zůstává majetkem zadavatele. Zadavatel neuděluje instituci žádná výslovná ani předpokládaná práva duševního vlastnictví k hodnocenému léčivému přípravku ani k jakékoliv metodě přípravy a použití hodnoceného léčivého přípravku.

Ownership of Sponsor Drug. Sponsor Drug is and remains the property of Sponsor. Sponsor grants Institution and Principal Investigator no express or implied intellectual property rights in the Sponsor Drug or in any methods of making or using the Sponsor Drug.5.4